|69.39||-1.53||-2.16%||Vol 439.74K||1Y Perf 92.18%|
|Apr 9th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||102.40||Analyst Rating||Strong Buy 1.25|
|Potential %||47.57||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||100/-54/-81||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||100/-46/-91||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||100/-48/-91||Income Ranking||— -|
|Market Cap||4.31B||Earnings Rating||Sell|
|Price Range Ratio 52W %||54.46||Earnings Date||6th May 2021|
Today's Price Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th May 2021|
|Estimated EPS Next Report||-2.94|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||705.30K|
|Avg. Monthly Volume||806.24K|
|Avg. Quarterly Volume||677.96K|
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) stock closed at 69.39 per share at the end of the most recent trading day (a -2.16% change compared to the prior day closing price) with a volume of 439.78K shares and market capitalization of 4.31B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 647 people. Biohaven Pharmaceutical Holding Company Ltd. CEO is Vlad Coric.
The one-year performance of Biohaven Pharmaceutical Holding Company Ltd. stock is 92.18%, while year-to-date (YTD) performance is -19.04%. BHVN stock has a five-year performance of %. Its 52-week range is between 31.86 and 100.77, which gives BHVN stock a 52-week price range ratio of 54.46%
Biohaven Pharmaceutical Holding Company Ltd. currently has a PE ratio of -5.20, a price-to-book (PB) ratio of 29.80, a price-to-sale (PS) ratio of 68.55, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -144.43%, a ROC of -751.37% and a ROE of 384.89%. The company’s profit margin is -%, its EBITDA margin is -2 196.10%, and its revenue ttm is $62.48 Million , which makes it $0.97 revenue per share.
Of the last four earnings reports from Biohaven Pharmaceutical Holding Company Ltd., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-2.94 for the next earnings report. Biohaven Pharmaceutical Holding Company Ltd.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Biohaven Pharmaceutical Holding Company Ltd. is Strong Buy (1.25), with a target price of $102.4, which is +47.57% compared to the current price. The earnings rating for Biohaven Pharmaceutical Holding Company Ltd. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Biohaven Pharmaceutical Holding Company Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Biohaven Pharmaceutical Holding Company Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 6.20, ATR14 : 5.01, CCI20 : -61.88, Chaikin Money Flow : -0.15, MACD : -1.14, Money Flow Index : 41.65, ROC : 2.57, RSI : 46.20, STOCH (14,3) : 38.49, STOCH RSI : 0.47, UO : 47.64, Williams %R : -61.51), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Biohaven Pharmaceutical Holding Company Ltd. in the last 12-months were: Charles Conway (Option Excercise at a value of $0), Declan Doogan (Sold 600 000 shares of value $39 365 594 ), Elyse Stock (Option Excercise at a value of $957 511), Elyse Stock (Sold 36 966 shares of value $2 396 501 ), Gregory Hugh Bailey (Option Excercise at a value of $4 107 876), Gregory Hugh Bailey (Sold 850 000 shares of value $62 243 678 ), James Engelhart (Option Excercise at a value of $440 755), James Engelhart (Sold 73 725 shares of value $4 872 601 ), John Tilton (Option Excercise at a value of $483 080), John Tilton (Sold 52 000 shares of value $3 504 000 ), John W. Childs (Buy at a value of $5 966 821), Kimberly Gentile (Option Excercise at a value of $358 315), Kimberly Gentile (Sold 48 500 shares of value $3 549 059 ), Robert Berman (Option Excercise at a value of $201 000), Robert Berman (Sold 125 000 shares of value $9 406 626 ), Vlad Coric (Option Excercise at a value of $0), William B.J. Jones (Option Excercise at a value of $1 521 600), William B.J. Jones (Sold 30 000 shares of value $2 286 676 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.